Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
ELVN
Stock Latest News
Ratings
Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning
10d ago
ELVN
Premium
The Fly
Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress
10d ago
ELVN
Premium
The Fly
Guggenheim starts Enliven with Buy on leukemia opportunity
11d ago
ELVN
Premium
The Fly
Enliven initiated with a Buy at Guggenheim
11d ago
ELVN
Premium
The Fly
Enliven price target raised to $59 from $41 at Goldman Sachs
14d ago
ELVN
Premium
Ratings
Phil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029
14d ago
ELVN
Premium
Ratings
Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
15d ago
ELVN
Premium
The Fly
Enliven reports Q1 EPS (38c) vs. (57c) last year
15d ago
ELVN
Premium
The Fly
Merck comments on TERN-701 positive for Enliven’s ELVN-001, says Mizuho
22d ago
MRK
ELVN
Premium
The Fly
Enliven price target raised to $55 from $36 at Clear Street
26d ago
ELVN
Premium
Ratings
Enliven Therapeutics: Strengthening ELVN-001 Profile and M&A Optionality Support Buy Rating and $56 Price Target
1M ago
ELVN
Premium
Ratings
Leveraging Merck–Terns Benchmark: Supporting Enliven’s ELVN-001 Upside and a Raised $60 Buy Target
2M ago
ELVN
Premium
The Fly
Enliven rises 11.0%
2M ago
ELVN
Premium
The Fly
Enliven price target raised to $56 from $48 at H.C. Wainwright
2M ago
ELVN
Premium
The Fly
Clear Street says Merck’s bet on TERN-701 sharpens investment case for ELVN-001
2M ago
MRK
NVS
Premium
The Fly
Video: Arm jumps as analysts react favorably to business model shift, guidance
2M ago
ARM
MRK
Premium
The Fly
Enliven up 20% after Terns Pharmaceuticals agrees to be bought by Merck
2M ago
MRK
ELVN
Premium
The Fly
Enliven price target raised to $45 from $41 at Mizuho
2M ago
ELVN
Premium
Ratings
Enliven Therapeutics: Compelling Early ELVN-001 Data and De-Risked Development Path Support Buy Rating
3M ago
ELVN
Premium
Ratings
Enliven Therapeutics: Compelling ELVN-001 CML Data, Strong Cash Runway Support Buy Rating
3M ago
ELVN
Premium
The Fly
Enliven reports Q4 EPS (48c), consensus (47c)
3M ago
ELVN
Premium
Ratings
Enliven Therapeutics: Robust ELVN-001 CML Data, Clear Pivotal Path, and Solid Cash Runway Support Buy Rating
4M ago
ELVN
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.